靶向BCMA的单克隆抗体在多发性骨髓瘤中的研究进展:2021年更新
本文综述靶向B细胞成熟抗原(BCMA)的单克隆抗体——双特异性抗体(bsAb)与抗体偶联药物(ADC)——在多发性骨髓瘤中的临床前与首次人体试验数据,并梳理其结构与作用机制。belantamab mafodotin成为首个获FDA批准的抗BCMA药物,用于复发/难治性MM。
要点
- BCMA仅表达于成熟B淋巴细胞和浆细胞,是免疫治疗的理想新靶点。
- belantamab mafodotin获FDA批准用于复发/难治性MM,为首个抗BCMA药物。
- bsAb与ADC单药在重度经治患者中显示疗效,具深度持久缓解潜力。
核心结论
- 靶向BCMA的bsAb与ADC单药在重度经治MM中显示疗效,具深度持久缓解潜力。
- belantamab mafodotin获FDA批准用于复发/难治性MM,为首个抗BCMA药物。
研究设计与样本
- 综述,聚焦靶向BCMA的单克隆抗体(bsAb与ADC),汇总临床前研究及首次人体临床试验数据。
主要发现
- bsAb、ADC与CAR-T三类BCMA靶向疗法单药在重度经治患者中均显示疗效。
- BCMA仅表达于成熟B淋巴细胞和浆细胞,为理想免疫治疗靶点。
关键数值与推荐
- belantamab mafodotin获美国FDA批准用于复发/难治性MM,为首个抗BCMA药物。
临床怎么用
- BCMA靶向bsAb与ADC可用于重度经治复发/难治MM的单药治疗。
- 现有结果为基础,支持开展联合方案临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Remarkable advances have been achieved in the treatment of multiple myeloma (MM) in the last decade, which saw targeted immunotherapy, represented by anti-CD38 monoclonal antibodies, successfully incorporated across indications. However, myeloma is still considered curable in only a small subset of patients, and the majority of them eventually relapse. B-cell maturation antigen (BCMA) is expressed exclusively in mature B lymphocytes and plasma cells, and represents an ideal new target for immunotherapy, presented by bispecific antibody (bsAb) constructs, antibody-drug conjugates (ADCs) and chimeric antigen receptor T (CAR-T) cells. Each of them has proved its efficacy with the potential for deep and long-lasting responses as a single agent therapy in heavily pretreated patients. As a result, belantamab mafodotin was approved by the United States Food and Drug Administration for the treatment of relapsed/refractory MM, as the first anti-BCMA agent. In the present review, we focus on monoclonal antibodies targeting BCMA - bsAbs and ADCs. The data from preclinical studies as well as first-in-human clinical trials will be reviewed, together with the coverage of their constructs and mechanisms of action. The present results have laid the groundwork for the ongoing or upcoming clinical trials with combinatory regimens, which have always been a cornerstone in the treatment of MM.
引用
- Demel I, Bago JR, Hajek R, et al. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. Br J Haematol. 2020. PMID: 33216972. doi:10.1111/bjh.17235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。